Human Receptor-Interacting Serine / Threonine-Protein Kinase 2 ( RIPK 2 ) A Target Enabling Package ( TEP )

Gene ID / UniProt ID / EC 8767 / O43353 / Target Nominator SGC Internal Nomination SGC Authors Peter Canning, Daniel M. Pinkas, Joshua C. Bufton, Sarah Picaud, Jennifer A. Ward, Catherine Rogers, Benedict-Tilman Berger, Stefan Knapp, Susanne Muller-Knapp, Paul E. Brennan, Kilian V. M. Huber, Panagis Filippakopoulos, Alex N. Bullock Collaborating Authors Matous Hrdinka, Qui Ruan, Chalada Suebsuwong, Lisa Schlicher, Bing Dai, Jenny L. Maki, Soumya S. Ray, Danish Saleh, Sameer Nikhar, Tobias Schwerd, Holm H.Uhlig, Gregory D. Cuny, Alexei Degterev, Mads Gyrd-Hansen Target PI Alex N. Bullock (SGC Oxford) Therapeutic Area(s) Inflammatory diseases Disease Relevance Mutations in the NOD2-RIPK2 pathway identify RIPK2 a potential therapeutic target in auto-immune and inflammatory conditions such as Crohn’s disease, Blau syndrome, early-onset osteoarthritis and multiple sclerosis. Date Approved by TEP Evaluation Group 13 June 2018